Strategic Plan for Lung Vascular Research An NHLBI-ORDR Workshop Report

The Division of Lung Diseases of the National Heart, Lung, and Blood Institute, with the Office of Rare Diseases Research, held a workshop to identify priority areas and strategic goals to enhance and accelerate research that will result in improved understanding of the lung vasculature, translation...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of respiratory and critical care medicine Vol. 182; no. 12; pp. 1554 - 1562
Main Authors ERZURUM, Serpil, ROUNDS, Sharon I, BOGAARD, Harm, CHOUDHARY, Gaurav, DORN, Gerald W, DWEIK, Raed, FAGAN, Karen, FALLON, Michael, FINKEL, Toren, GERACI, Mark, GLADWIN, Mark T, HASSOUN, Paul M, STEVENS, Troy, HUMBERT, Marc, KAMINSKI, Naftali, KAWUT, Steven M, LOSCALZO, Joseph, MCDONALD, Donald, MCMURTRY, Ivan F, NEWMAN, John, NICOLLS, Mark, RABINOVITCH, Marlene, SHIZURU, Judy, ALDRED, Micheala, OKA, Masahiko, POLGAR, Peter, RODMAN, David, SCHUMACKER, Paul, STENMARK, Kurt, TUDER, Rubin, VOELKEL, Norbert, SULLIVAN, Eugene, WEINSHILBOUM, Richard, YODER, Mervin C, ALIOTTA, Jason, YINGMING ZHAO, GAIL, Dorothy, MOORE, Timothy M, ARCHER, Stephen L, ASOSINGH, Kewal, BALABAN, Robert, BAUER, Natalie, BHATTACHARYA, Jahar
Format Journal Article
LanguageEnglish
Published New York, NY American Thoracic Society 15.12.2010
Subjects
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
Biological and medical sciences
Biology
Biomedical Research - methods
Emergency and intensive care: injuries, diseases due to physical agents. Diving. Drowning. Disaster medicine
Epigenetics
Gene expression
Guidelines as Topic
Humans
Intensive care medicine
Kinases
Lung - blood supply
Lung diseases
Lung Diseases - physiopathology
Medical sciences
Mutation
Nhlbi Workshop
Proteins
Pulmonary arteries
Pulmonary Circulation
Pulmonary hypertension
Intensive care
Respiratory disease
Cardiovascular disease
genomics
ventricle
Metabolism
phenotyping
Pulmonary hypertension
Resuscitation
Online AccessGet full text

Cover

More Information
Summary:The Division of Lung Diseases of the National Heart, Lung, and Blood Institute, with the Office of Rare Diseases Research, held a workshop to identify priority areas and strategic goals to enhance and accelerate research that will result in improved understanding of the lung vasculature, translational research needs, and ultimately the care of patients with pulmonary vascular diseases. Multidisciplinary experts with diverse experience in laboratory, translational, and clinical studies identified seven priority areas and discussed limitations in our current knowledge, technologies, and approaches. The focus for future research efforts include the following: (1) better characterizing vascular genotype-phenotype relationships and incorporating systems biology approaches when appropriate; (2) advancing our understanding of pulmonary vascular metabolic regulatory signaling in health and disease; (3) expanding our knowledge of the biologic relationships between the lung circulation and circulating elements, systemic vascular function, and right heart function and disease; (4) improving translational research for identifying disease-modifying therapies for the pulmonary hypertensive diseases; (5) establishing an appropriate and effective platform for advancing translational findings into clinical studies testing; and (6) developing the specific technologies and tools that will be enabling for these goals, such as question-guided imaging techniques and lung vascular investigator training programs. Recommendations from this workshop will be used within the Lung Vascular Biology and Disease Extramural Research Program for planning and strategic implementation purposes.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Originally Published in Press as DOI: 10.1164/rccm.201006-0869WS on October 8, 2010
This article has an online supplement, which is accessible from this issue's table of contents at www.atsjournals.org
Supported by the Division of Lung Diseases, National Heart, Lung, and Blood Institute, NIH, Office of Rare Diseases Research, Office of the Director, NIH.
Author Disclosure: S.E. received more than $100,001 from Asthmatx as an investigator industry-sponsored grant. SIR received more than $100,001 from the NHLBI in sponsored grants and up to $1,000 from the NHLBI in consultancy fees as a study section member. T.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.A. received more than $100,001 from the NIH/NHLBI and more than $100,001 from the AHA in sponsored grants. J.A. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.L.A. holds patents related to the use of PDK inhibitors to treat cancer, but these have not been commercialized. K.A. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.S.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. N.B. received $50,001–$100,000 from Gilead in industry-sponsored grants for the Research Scholars Program, and $10,001–$50,000 from the Parker B. Francis Foundation as a fellowship and $50,001–$100,000 from the American Heart Association as a beginning grant-in-aid. J.B. received up to $1,000 from Chromocell Corporation in consultancy fees and more than $100,001 from the NIH in RO1, RC1 grants. H.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. G.C. received $50,001–$100,000 from Actelion Pharmaceuticals in industry-sponsored grants as the Entelligence Young Investigator Award-2008 and is an employee of the Department of Veteran Affairs. G.W.D. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.D. received more than $100,001 from Actelion, more than $100,001 from Gilead, and more than $100,001 from Novartis in industry-sponsored grants, and more than $100,001 from the NIH and more than $100,001 from the State of Ohio in sponsored grants. K.F. received up to $1,000 from Cytoskeleton for a phone consult concerning a research compound, $1,001–$5,000 from Pfizer for serving as a research committee member, and $10,001–$50,000 from Gilead for serving on a research committee (twice) and as an advisory board panelist, $5,010–$10,000 from Gilead in promotional lecture fees, and $1,001–$5,000 from ABComm and $1,001–$5,000 from Simply Speaking for CME lecture fees, $50,001–$100,000 from Actelion and $50,001–$100,000 from Gilead in institutional grants, up to $1,000 from Up-to-Date in royalties as a chapter author, and $50,001–$100,000 from the NIH (RO1s) and $50,001–$100,000 from the AHA (EIA) in sponsored grants, and up to $1,000 from the PHA in advisory board fees for serving as a journal writer and editor. M.F. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. T.F. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.G. received $1,001–$5,000 from Mindstar-Medical-Bayer for serving on the Bayer Riociguat Pulm Clin Advisory Board; M.G.'s institution received more than $100,001 from the NIH in sponsored grants. M.T.G. received $50,001–$100,000 from the Collaborative Research and Development Agreement between the U.S. government and INO Therapeutics in industry-sponsored grants and holds a patent from the U.S. government as a coinventor for use of nitrite salts for cardiovascular indications. P.M.H. received $1,001–$5,000 from Novartis for serving on an advisory board, $1,001–$5,000 from Abcomm in lecture fees for Medical Grand Rounds, $50,001–$100,000 from Actelion/UT in industry-sponsored grants for the PAH registry (REVEAL), and more than $100,001 from the NIH/NHLBI in sponsored grants for the Specialized Center for Clinically Oriented Research (SCCOR). M.H. received $5,001–$10,000 from Actelion and $1,001–$5,000 from Novartis in consultancy fees, $5,001–$10,000 from Actelion, and $1,001–$5,000 from Novartis in advisory board fees, and $1,001–$5,000 from Actelion, $1,001–$5,000 from Bayer Schering, $1,001–$5,000 from GlaxoSmithKline, $1,001–$5,000 from Pfizer, and $1,001–$5,000 from United Therapeutics in lecture fees. N.K. has received consultancy fees from Stromedix and Genentech (each $1,001–$5,000); he has received industry-sponsored grants from Biogen Idec and Centocor (each more than $100,000); he holds three patents along with the University of Pittsburgh (related to use of microRNAs in treatment and diagnosis of IPF, peripheral blood biomarkers in IPF, and urinary biomarkers in IPF); he holds sponsored grants from the NIH (over $100,000). S.K. has received consultancy fees from Gilead and Novartis (each $1,001–$5,000); he has received advisory board fees from Bayer and Gilead (each $1,001–$5,000); he has received steering committee fees from Gilead ($10,001–$50,000); he has received grant review committee fees from Gilead ($10,001–$50,000) and Pfizer ($5,001–$10,000); he has received lecture fees from Gilead ($1,001–$5,000) and Actelion ($1,001–$5,000); he has received industry-sponsored grants from Actelion, Gilead, United Therapeutics, Lung Rx, and Pfizer (each $10,001–$50,000); he has received fees from Pfizer as a collaborator on an institutional grant (F) ($50,001–$100,000), from Merck for a drug study for an NIH-funded grant (F) ($10,001–$50,000), and from Bayer for a drug study for an NIH-funded grant (F) ($5001–$10,000); he has received sponsored grants from the NIH (more than $100,000); he has received advisory board fees from the American Lung Association ($1,001–$5,000); he has received advisory board fees from the NIH (up to $1000). J.L. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. D.M.M. has received industry-sponsored grants from MedImmune (more than $100,000). I.F.M. has received consultancy fees from Cytokinetics (up to $1,000); he has received sponsored grants from the American Heart Association ($10,001–$50,000). J.N. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.N. has received sponsored grants from the NIH (more than $100,000). M.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.S. has received consultancy fees from Stem Cells, Inc. ($1,001–$5,000); she has received sponsored grants from the NIH, CIRM, and Council for Tobacco Research (each more than $100,000). M.O. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. P.P. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. D.R. is employed by Novartis Institutes for BM Res; he holds patents along with Novartis AG; he holds restricted stock grants from Novartis AG (more than $100,000). P.T.S. has received sponsored grants from the NIH (more than $100,000), Chicago Biomed Consort (more than $100,000), American Academy of Pediatricians ($10,001–$50,000), and American Heart Association ($50,001–$100,000). K.S. has received sponsored grants from Pfizer (more than $100,000) and the NHLBI/NIH (more than $100,000). R.M.T. has received consultancy fees from Novartis (up to $1,000); he has received sponsored grants from the NIH (more than $100,000). N.V. has received consultancy fees from Bayer-Schering and Pfizer (each $1,001–$5,000). E.S. is employed by United Therapeutics Corporation; he has applied for a patent along with United Therapeutics Corporation; he holds stock in United Therapeutics Corporation (more than $100,000). R.W. has received royalties from Laboratory Corporation of America and Ricerca Biosciences LLC (up to $1,000). M.C.Y. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Y.Z. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. D.B.G. is a full-time employee of the NIH. T.M.M. has received sponsored grants from the American Heart Association ($50,001–$100,000) and the Parker B. Francis Foundation ($50,001–$100,000).
ISSN:1073-449X
1535-4970
DOI:10.1164/rccm.201006-0869WS